Indivior Pharmaceuticals, Inc. INDV Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $175M-10.3% | $195M-56.2% | $445M-12.7% | $510M+37.1% | $372M+16.6% | ||
| $273M+7.9% | $253M-2.3% | $259M+7.9% | $240M-1.2% | $243M-4.3% | ||
| $1M-50.0% | $2M+100% | $1M-94.1% | $17M+41.7% | $12M+20.0% | ||
| $59M+20.4% | $49M+14.0% | $43M+16.2% | $37M-5.1% | $39M-23.5% | ||
| $69M-8.0% | $75M-8.5% | $82M-12.8% | $94M-9.6% | $104M+10.6% | ||
| $15M-55.9% | $34M+13.3% | $30M+7.1% | $28M-50.0% | $56M+5.7% | ||
| $12M+500% | $2M-84.6% | $13M+333% | $3M-89.7% | $29M-12.1% | ||
| $667M+2.3% | $652M-29.3% | $922M-3.0% | $951M+7.7% | $883M+6.8% | ||
| $157M+9.0% | $144M+16.1% | $124M+6.0% | $117M+12.5% | $104M+4.0% | ||
| $111M+3.7% | $107M+0.9% | $106M+14.0% | $93M+1.1% | $92M+2.2% | ||
| $22M-15.4% | $26M-13.3% | $30M-14.3% | $35M-5.4% | $37M-5.1% | ||
| $2M0.0% | $2M0.0% | $2M-71.4% | $7M0.0% | $7M+16.7% | ||
| $296M-8.4% | $323M+13.3% | $285M+5.6% | $270M-3.2% | $279M+0.7% | ||
| $26M-3.7% | $27M0.0% | $27M-38.6% | $44M+12.8% | $39M0.0% | ||
| $27M-3.6% | $28M0.0% | $28M+3.7% | $27M0.0% | $27M0.0% | ||
| $1.2B-0.3% | $1.2B-15.2% | $1.42B-2.5% | $1.45B+5.6% | $1.38B+4.5% | ||
| $35M-27.1% | $48M+17.1% | $41M-18.0% | $50M+8.7% | $46M-27.0% | ||
| $42M-59.2% | $103M+30.4% | $79M+38.6% | $57M+26.7% | $45M+309% | ||
| $0-100% | $29M+61.1% | $18M0.0% | $18M0.0% | $18M0.0% | ||
| $9M-10.0% | $10M0.0% | $10M-9.1% | $11M0.0% | $11M+10.0% | ||
| $26M+1,200% | $2M-50.0% | $4M-76.5% | $17M+41.7% | $12M+71.4% | ||
| $779M-14.8% | $914M-5.3% | $965M-8.6% | $1.06B+5.1% | $1.01B+8.8% | ||
| $486M+67.6% | $290M-4.6% | $304M-1.3% | $308M-1.0% | $311M-1.3% | ||
| $14M-36.4% | $22M-8.3% | $24M-17.2% | $29M-3.3% | $30M-6.3% | ||
| —— | $32M— | —— | —— | —— | ||
| $21M0.0% | $21M-30.0% | $30M+66.7% | $18M+5.9% | $17M-5.6% | ||
| $1.34B+3.2% | $1.3B-19.9% | $1.62B-5.0% | $1.71B+3.0% | $1.66B+0.5% | ||
| $0-100% | $62M0.0% | $62M0.0% | $62M0.0% | $62M0.0% | ||
| $165M+47.3% | $112M+2.8% | $109M+7.9% | $101M+8.6% | $93M+3.3% | ||
| -$280M-15.2% | -$243M+29.8% | -$346M+10.8% | -$388M+4.4% | -$406M+8.4% | ||
| -$29M+3.3% | -$30M+6.3% | -$32M+3.0% | -$33M+5.7% | -$35M+2.8% | ||
| -$144M-46.9% | -$98M+52.7% | -$207M+19.5% | -$257M+9.8% | -$285M+15.4% | ||
| $1.2B-0.3% | $1.2B-15.2% | $1.42B-2.5% | $1.45B+5.6% | $1.38B+4.5% | ||
| $3M-25.0% | $4M+100% | $2M0.0% | $2M0.0% | $2M-33.3% | ||
| $3M-25.0% | $4M+100% | $2M0.0% | $2M0.0% | $2M-33.3% | ||
| $69M-8.0% | $75M-8.5% | $82M-12.8% | $94M-9.6% | $104M+10.6% | ||
| $40M+150% | $16M-15.8% | $19M-5.0% | $20M0.0% | $20M-4.8% | ||
| $26M-3.7% | $27M0.0% | $27M-38.6% | $44M+12.8% | $39M0.0% | ||
| $2M0.0% | $2M0.0% | $2M-71.4% | $7M0.0% | $7M+16.7% | ||
| $22M-15.4% | $26M-13.3% | $30M-14.3% | $35M-5.4% | $37M-5.1% | ||
| $296M-8.4% | $323M+13.3% | $285M+5.6% | $270M-3.2% | $279M+0.7% | ||
| $2M0.0% | $2M0.0% | $2M-71.4% | $7M0.0% | $7M+16.7% | ||
| $27M-3.6% | $28M0.0% | $28M+3.7% | $27M0.0% | $27M0.0% | ||
| $22M-15.4% | $26M-13.3% | $30M-14.3% | $35M-5.4% | $37M-5.1% | ||
| $26M-3.7% | $27M0.0% | $27M-38.6% | $44M+12.8% | $39M0.0% | ||
| $268M+6.8% | $251M+9.1% | $230M+9.5% | $210M+6.6% | $197M+3.7% | ||
| $22M-15.4% | $26M-13.3% | $30M-14.3% | $35M-5.4% | $37M-5.1% | ||
| $26M-3.7% | $27M0.0% | $27M-38.6% | $44M+12.8% | $39M0.0% | ||
| $41M-21.2% | $52M-82.7% | $300M+0.3% | $299M+0.7% | $297M-18.6% | ||
| $42M-59.2% | $103M+30.4% | $79M+38.6% | $57M+26.7% | $45M-25.0% | ||
| $551M-5.3% | $582M-5.1% | $613M-13.5% | $709M+5.0% | $675M+20.1% | ||
| $178M-28.8% | $250M+16.3% | $215M+9.7% | $196M+7.1% | $183M-15.3% | ||
| $26M+1,200% | $2M-50.0% | $4M-76.5% | $17M+41.7% | $12M+71.4% | ||
| $42M-59.2% | $103M+30.4% | $79M+38.6% | $57M+26.7% | $45M-25.0% | ||
| $92M+21.1% | $76M+26.7% | $60M+11.1% | $54M— | —— | ||
| $14M-66.7% | $42M-60.4% | $106M+1.0% | $105M0.0% | $105M+6.1% | ||
| $509M+45.0% | $351M-1.4% | $356M-2.7% | $366M-1.1% | $370M-1.3% | ||
| $5M0.0% | $5M-86.1% | $36M-2.7% | $37M— | —— | ||
| $0.00-99.8% | $0.500.0% | $0.500.0% | $0.500.0% | $0.500.0% | ||
| 122M-2.4% | 125M0.0% | 125M0.0% | 125M0.0% | 125M0.0% | ||
| $0-100% | $62M0.0% | $62M0.0% | $62M0.0% | $62M0.0% | ||
| $30.86— | —— | —— | —— | —— | ||
| $268M+6.8% | $251M+9.1% | $230M+9.5% | $210M+6.6% | $197M+3.7% | ||
| $92M+21.1% | $76M+26.7% | $60M+11.1% | $54M— | —— | ||
| $3M-25.0% | $4M+100% | $2M0.0% | $2M0.0% | $2M-33.3% | ||
| 100%— | —— | —— | —— | —— | ||
| $0-99.8% | $0.50.0% | $0.50.0% | $0.50.0% | $0.50.0% | ||
| $122M-2.4% | $125M0.0% | $125M0.0% | $125M0.0% | $125M0.0% | ||
| $551M-5.3% | $582M-5.1% | $613M-13.5% | $709M+5.0% | $675M+20.1% | ||
| $12M+500% | $2M-84.6% | $13M+333% | $3M-89.7% | $29M-12.1% | ||
| $26M-16.1% | $31M-3.1% | $32M-8.6% | $35M+6.1% | $33M0.0% | ||
| $55M-41.5% | $94M-76.8% | $406M+0.5% | $404M+0.5% | $402M-13.4% | ||
| $41M-21.2% | $52M-82.7% | $300M+0.3% | $299M+0.7% | $297M-18.6% | ||
| $4M+33.3% | $3M-62.5% | $8M0.0% | $8M-88.4% | $69M+1,050% | ||
| $15M-55.9% | $34M+13.3% | $30M+7.1% | $28M-50.0% | $56M+80.6% | ||
| $30.86— | —— | —— | —— | —— | ||
| $154M0.0% | $154M-1.9% | $157M-4.8% | $165M-5.7% | $175M-1.7% | ||
| $5M0.0% | $5M-86.1% | $36M-2.7% | $37M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Indivior Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 0.86 — current liabilities exceed current assets.
- Where does Indivior Pharmaceuticals, Inc. 's balance sheet data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.